Please assess the completion status of the following clinical trial:

Trial Title: Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical indication for cardiac catheterization and SVG angiography~2. Presence of at least one SVG lesion of 30% to 60% diameter stenoses, by visual estimation, which is not the culprit lesion\* responsible for the clinical syndrome of the patient~   \*If the target lesion is located in the same SVG than the culprit lesion (if present) it has to be at least 4 cm far from the stented segment)~3. Written informed consent~Exclusion Criteria:~1. Patient \< 18 years old~2. Ejection fraction \< 30%~3. Renal insufficiency with creatinine \> 200 μmol/l~4. Presence of more than 2 moderate SVG stenoses in a single SVG or significant diffuse SVG disease defined as disease covering more than half of the length of the SVG~5. Presence of more than 2 SVGs with moderate SVG stenoses~6. Unsuccessful angioplasty (residual stenosis \>30% and/or TIMI flow \<3) of any other lesion treated during the same procedure (culprit lesions will be treated before patient randomization)~7. Any significant complication occurring during the angioplasty of the culprit lesion(s) during the same procedure~8. SVG lesion located at the distal anastomosis~9. SVG lesions located at the proximal anastomosis (lesion length \< 5 mm from the SVG ostium)~10. Lesion length \>25 mm~11. SVGs ≤ 3 years ago~12. Cardiogenic shock~13. Remaining coronary or SVG lesion(s) with treatment (PCI or CABG) planned within the following year~14. Pregnancy~15. Contraindication to aspirin and/or thienopyridine/ticagrelor treatment~16. Allergy to paclitaxel~17. Any disease with a limiting life-expectancy (less than 2 years)~18. Need for chronic anticoagulation treatment~19. Definite presence or high suspicion of thrombus or ulceration in the target lesion~20. Target lesion located in the same SVG as the culprit lesion (if present) and distance between the target lesion and the most proximal or distal part of the stent implanted at the culprit lesion \< 4 cm~21. Vein graft diameter \< 2.5 mm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCI-stenting (Type: EXPERIMENTAL): Stenting the moderate SVG lesion with the paclitaxel stent
- Standard medical treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).